Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 gene during very low calorie diet in obese subjects

被引:26
作者
Bastard, JP
Vidal, H
Jardel, C
Bruckert, E
Robin, D
Vallier, P
Blondy, P
Turpin, G
Forest, C
Hainque, B
机构
[1] Hop La Pitie Salpetriere, Serv Biochim Pf J Delattre, AP HP, F-75013 Paris, France
[2] RTH Laennec, INSERM U449, Fac Med, Lyon, France
[3] Hop Pitie, Serv Endocrinol, AP HP, F-75651 Paris, France
[4] CNRS, Ctr Rech Endocrinol Mol & Dev, Meudon, France
[5] Grp Hosp Pitie Salpetriere, Inst Federatif Rech Coeur Muscle & Vaisseaux, AP HP, F-75634 Paris, France
关键词
adipocyte; obesity; plasminogen activator inhibitor-1; calorie restriction;
D O I
10.1038/sj.ijo.0801087
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTlVE: To determine whether changes in subcutaneous adipose tissue plasminogen activator inhibitor-1 (PAI-1) expression influence plasma PAI-7 level during weight: loss in obese humans. DESIGN: Study of the variations of PAI-1 levels both in plasma and in subcutaneous abdominal adipose tissue in 15 volunteer non-diabetic obese subjects, body mass index (BMI) 40.4. +/- 1.9 kg/m(2), aged 48 +/- 3 y, before and after a 3 week. very low calorie diet: (VLCD) programme (3.9+/- 0.1 MJ/day). MEASUREMENTS: Plasma and adipose tissue PAI-1 protein revels were measured by enzyme-linked immunosorbent assay and PAI-1 mRNA levels were quantified by quantitative RT-competitive PCR. RESULTS: VLCD induced weight loss (5.8+/-0.8kg) and decreased plasma)PAI-1 concentration (- 26% (P<0.01). Surprisingly, PAI-1 mRNA and protein abundance in subcutaneous adipose tissue increased by 87% (P < 0.05) and by 44% (P < 0.01). respectively. CONCLUSION: These data indicate thus that changes in subcutaneous adipose tissue PAI-1 expression are not involved in the decrease of plasma PAI-1 levels during VLCD in obese subjects.
引用
收藏
页码:70 / 74
页数:5
相关论文
共 19 条
  • [1] Production of plasminogen activator inhibitor 1 by human adipose tissue - Possible link between visceral fat accumulation and vascular disease
    Alessi, MC
    Peiretti, F
    Morange, P
    Henry, M
    Nalbone, G
    JuhanVague, I
    [J]. DIABETES, 1997, 46 (05) : 860 - 867
  • [2] Auboeuf D, 1997, ANAL BIOCHEM, V245, P141, DOI 10.1006/abio.1996.9986
  • [3] Bastard JP, 1997, DIABETES METAB, V23, P87
  • [4] BASTARD JP, 1995, INT J OBESITY, V19, P836
  • [5] PERCUTANEOUS ADIPOSE-TISSUE BIOPSY BY MINI-LIPOSUCTION FOR METABOLIC STUDIES
    BASTARD, JP
    CUEVAS, J
    COHEN, S
    JARDEL, C
    HAINQUE, B
    [J]. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 1994, 18 (05) : 466 - 468
  • [6] Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction
    CallesEscandon, J
    Ballor, D
    HarveyBerino, J
    Ades, P
    Tracy, R
    Sobel, B
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1996, 64 (01) : 7 - 11
  • [7] Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals
    Eriksson, P
    Reynisdottir, S
    Lönnqvist, F
    Stemme, V
    Hamsten, A
    Arner, P
    [J]. DIABETOLOGIA, 1998, 41 (01) : 65 - 71
  • [8] IMPACT OF WEIGHT-LOSS ON PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1), FACTOR-VII, AND OTHER HEMOSTATIC FACTORS IN MODERATELY OVERWEIGHT ADULTS
    FOLSOM, AR
    QAMHIEH, HT
    WING, RR
    JEFFERY, RW
    STINSON, VL
    KULLER, LH
    WU, KK
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (02): : 162 - 169
  • [9] HAMSTEN A, 1987, LANCET, V2, P3
  • [10] Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women
    Janand-Delenne, B
    Chagnaud, C
    Raccah, D
    Alessi, MC
    Juhan-Vague, I
    Vague, P
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 1998, 22 (04) : 312 - 317